Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)

0
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/16/2014 07/17/2014 07/18/2014 07/21/2014 07/22/2014 Date
31.75(c) 31.875(c) 32.25(c) 32(c) 32.5 Last
13 894 7 750 18 173 19 512 2 906 570 Volume
-0.78% +0.39% +1.18% -0.78% +1.56% Change
More quotes
Company
Vernalis Plc is a research and development stage pharmaceutical company. The company provides pharmaceutical products for a range of medical disorders. It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development. The group has one marketed product,... 
Sector
Biotechnology & Medical Research
Calendar
08/05 | 02:00amEarnings Release
Surperformance© rating of Vernalis plc
Trading Rating : Investor Rating :
More about the company
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Financials ( GBP)
Sales 2014 10,3 M
EBIT 2014 -13,5 M
Net income 2014 -10,7 M
Finance 2014 31,4 M
Yield 2014 -
Sales 2015 14,0 M
EBIT 2015 -18,3 M
Net income 2015 -16,9 M
Finance 2015 20,6 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 10,7x
EV / Sales 2015 8,66x
Capitalization 142 M
More Financials
Latest news on VERNALIS PLC
6h ago VERNALIS : Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieve..
8h ago VERNALIS : 3rd Product in Cough Cold Pipeline Achieves POC
9h ago VERNALIS : Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proo..
5d ago VERNALIS : Notice of results for the six months ended 30 June 2014
5d ago VERNALIS : Notice of Results for 6 Months Ended 30 June 2014
5d ago VERNALIS : Notice of Results for the Six Months Ended 30 June 2014
07/13 VERNALIS : and Tri Pharma Submit Application to FDA for TuzistraTM XR
07/03 VERNALIS : and Tri Pharma Submit Application to FDA for TuzistraTM XR
06/30 VERNALIS : Submission of TuzistraTM XR (CCP-01) NDA to FDA
06/30 VERNALIS : *Vernalis, Tris Pharma Submit New Drug Application To US FDA For Tuzi..
06/30 VERNALIS : Submission of TuzistraTM XR (CCP-01) NDA to FDA
06/19 VERNALIS : Receives Milestone Payment From Phase I Trial Of Cancer Drug
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Technical analysis
Income Statement Evolution
Vernalis plc : Income Statement Evolution
More Financials
EPS Revisions
Vernalis plc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF